PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 679-685

  Koga, Hironori ^a,b   Selvendiran, Karuppaiyah ^a   Sivakumar, Ramadoss ^a   Yoshida, Takafumi ^a,b   Torimura, Takuji ^a,b   Ueno, Takato ^a   Sata, Michio ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Caspase; Chemotherapy; Death receptor; Hdac inhibitor; Peroxisome proliferator activated receptor; SiRNA; Synergy; Thiazolidinedione; Xenograft

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; DEATH RECEPTOR 5; FAS ANTIGEN; GEMCITABINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE; SMALL INTERFERING RNA; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DEOXYCYTIDINE; HISTONE DEACETYLASES; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PANCREATIC NEOPLASMS; PPAR GAMMA; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; THIAZOLIDINEDIONES; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857183125     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1237     Document Type: Article

References (27)

1. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
3. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D and Sarkar FH: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2011.
4. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4: 1046-1052, 1998. (Pubitemid 28417337)
5. KiP1 in human pancreatic carcinoma cells. Cancer Res 60: 5558-5564, 2000.
6. Eibl G, Wente MN, Reber HA and Hines OJ: Peroxisome proliferator- activated receptor γ induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 287: 522-529, 2001. (Pubitemid 32917630)
7. INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33: 1087-1097, 2001.
8. Kristiansen G, Jacob J, Buckendahl AC, et al: Peroxisome proliferator- activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 12: 6444-6451, 2006. (Pubitemid 44799717)
9. Su CG, Wen X, Bailey ST, et al: A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389, 1999. (Pubitemid 29534322)
10. Nakanishi C and Toi M: Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005. (Pubitemid 40488635)
11. Fajas L, Egler V, Reiter R, et al: The retinoblastoma-histone deacetylase 3 complex inhibits PPARγ and adipocyte differentiation. Dev Cell 3: 903-910, 2002. (Pubitemid 35460789)
12. Annicotte JS, Iankova I, Miard S, et al: Peroxisome proliferator- activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26: 7561-7574, 2006. (Pubitemid 44547706)
13. Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37: 1086-1096, 2003.
14. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y and Kato S: Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. J Biol Chem 275: 33201-33204, 2000.
15. Kuramitsu Y, Taba K, Ryozawa S, et al: Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 30: 3367-3372, 2010.
16. Ioka T, Ikeda M, Ohkawa S, et al: GEST study group. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 29: (suppl) abstr 4007, 2011.
17. Long J, Zhang Y, Yu X, et al: Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15: 817-828, 2011.
18. Conroy T, Desseigne F, Ychou M, et al: Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
19. Moore MJ, Goldstein D, Hamm J, et al: National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007. (Pubitemid 46972777)
20. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422, 2009.
21. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610, 2010.
22. Saif MW: Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series. Anticancer Res 31: 1039-1042, 2011.
23. Kallifatidis G, Rausch V, Baumann B, et al: Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling. Gut 58: 949-963, 2009.
24. Banerjee S, Kong D, Azmi AS, et al: Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer 128: 1240-1250, 2011.
25. Pan X, Arumugam T, Yamamoto T, et al: Nuclear factor-κB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 14: 8143-8151, 2008.
26. Bao B, Wang Z, Li Y, et al: Complexities of obesity and diabetes mellitus with the development and progression of pancreatic cancer. Biochim Biophys Acta 1815: 135-146, 2011.
27. Mamaghani S, Patel S and Hedley DW: Glycogen synthase kinase-3 inhibition disrupts nuclear factor-κB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 9: 132, 2009.